Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim

Federal Trade Commission, joined by seven state regulators, filed a motion asking a federal judge to find former biotech executive Martin Shkreli in contempt. The filing alleges that Shkreli, popularly known as “Pharma Bro,” violated a lifetime ban that bars him from participating in any pharmaceutical‑industry activities. The motion specifically cites alleged actions that influenced biopharma stock prices, prompting the regulators to seek a formal contempt finding. Coverage of the contempt motion appears across a broad set of outlets. Bloomberg.com and CNBC also reported that the FTC and states say Shkreli violated his lifetime pharma ban.

The consistency of the headline across these sources underscores the regulators’ coordinated effort and the focus on alleged stock‑influencing conduct. The backdrop to this filing is Shkreli’s earlier lifetime prohibition from the pharmaceutical sector, imposed after prior regulatory actions that barred him from any industry involvement. That ban makes any direct or indirect participation in pharma‑related business, including attempts to sway market prices of biotech firms, a clear violation. The current allegation suggests Shkreli engaged in activities that could affect biopharma equities, thereby breaching the terms of his ban and prompting the FTC and state agencies to pursue contempt enforcement. The next procedural step will be a judicial hearing on the contempt motion.

Observers will watch for the judge’s ruling on whether Shkreli’s conduct meets the legal threshold for contempt. Further statements from the FTC or the participating states, as well as any response from Shkreli’s legal team, are expected to follow. The outcome could determine additional penalties or enforcement measures tied to the lifetime ban.